ReviewTherapeutics and clinical risk management2023
Medications and Food Interfering with the Bioavailability of Levothyroxine: A Systematic Review.
Review in Therapeutics and clinical risk management, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism.European thyroid journal · 2025Guideline
- Single Center, Open-Label, Randomized Crossover Trial on Drug-Drug Interactions of Levothyroxine/Magnesium-Citrate and Levothyroxine/Magnesium-Aspartate in Healthy Subjects-The ThyroMag Trial.Clinical and translational science · 2025Trial
- The patient journey of adolescents and young adults with thyroid cancer: A social media listening study in China.Asia-Pacific journal of oncology nursing · 2026Article
- Antibiotics and the Endocrine System: Mechanisms, Adverse Effects, and Clinical Implications.Antibiotics (Basel, Switzerland) · 2026Review
- Iodine and Thyroid Dysfunction in Ageing: Nutritional, Pharmacologic, and Microbial Modifiers in Older Adults.Geriatrics (Basel, Switzerland) · 2026Review
- Understanding the Drivers of Hypothyroidism in Patients Undergoing Chronic Hemodialysis.Diagnostics (Basel, Switzerland) · 2026Article
- The gut-thyroid axis: physiological regulation of barrier function, microbiota, endocrine signaling and the consequences on energy metabolism.Frontiers in physiology · 2026Review
- Machine learning to predict food effects during drug development: a comprehensive review.Journal of cheminformatics · 2025Review
- Italian guidelines for the management of adult individuals with primary hypothyroidism outside pregnancy.Journal of endocrinological investigation · 2025Article
- Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system.PloS one · 2025Article
- Phosphate Binder Impairs Levothyroxine Absorption in a Hypothyroid Patient With End-Stage Renal Disease.Cureus · 2024Article
- Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.International journal of molecular sciences · 2023Review
- The challenges of returning to work for differentiated thyroid cancer survivors in china: a qualitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Levothyroxine personalized treatment: is it still a dream?Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Levothyroxine is a common prescribed drug. Many medications and food, however, can interfere with its bioavailability. The aim of this review was to summarize the medications, food and beverages that interact with levothyroxine and to assess their effects, mechanisms and treatments. Methods: A systematic review on interfering substances that interact with levothyroxine was performed. Web of Science, Embase, PubMed, the Cochrane library, grey literature from other sources and the lists of references were searched for human studies comparing the levothyroxine efficacy with and without interfering substances. The patient characteristics, drug classes, effects and mechanism were extracted. The NHLBI study quality assessment tools and the JBI critical appraisal checklist were used to assess the quality of included studies. Results: A total of 107 articles with 128 studies were included. Drugs interactions were revealed in calcium and iron supplements, proton pump inhibitors, bile acid sequestrants, phosphate binders, sex hormones, anticonvulsants and other drugs. Some food and beverage could also induce malabsorption. Proposed mechanisms included direct complexing, alkalization, alteration of serum thyroxine-binding globulin levels and acceleration of levothyroxine catabolism via deiodination. Dose adjustment, administration separation and discontinuation of interfering substances can eliminate the interactions. Liquid solutions and soft-gel capsules could eliminate the malabsorption due to chelation and alkalization. The qualities of most included studies were moderate. Conclusion: Lots of medications and food can impair the bioavailability of levothyroxine. Clinicians, patients and pharmaceutical companies should be aware of the possible interactions. Further well-designed studies are needed to provide more solid evidence on treatment and mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.